Literature DB >> 3698162

Disposition and metabolism of the antitumor glycoside phyllanthoside in mouse and beagle dog.

D J Moore, G Powis.   

Abstract

Phyllanthoside is a naturally occurring glycoside with activity against IP transplantable murine tumors. Phyllanthoside administered IV, to mice at a nontoxic dose of 16 mg/kg could not be detected in blood or plasma even 30 s after administration. There was rapid formation of a less polar metabolite, which disappeared with a half-life of about 10 min. When phyllanthoside was administered as an IV bolus to beagle dogs at doses of 0.1, 0.5, and 3.0 mg/kg the mean half-life of phyllanthoside elimination from plasma was 1.3 min and total body clearance 85.8 ml min-1 kg-1. A second phase of elimination was seen but could not be accurately defined. Only trace amounts of the less polar metabolite were detected in dog plasma. Infusion of phyllanthoside to beagle dogs at doses of 0.5 and 3.0 mg/kg over 70 min gave values for an initial half-life of 0.3 and 0.6 min, a terminal half-life of 99.4 and 16.5 min, and a total body clearance of 11.2 and 49.2 ml min-1 kg-1, respectively. The highest nontoxic dose of phyllanthoside in dog was 0.1 mg/kg, while doses of 0.5 mg/kg and 3.0 mg/kg resulted in ataxia and death of the dog. There was no difference in toxicity to dog according to whether phyllanthoside was given by IV bolus or continuous infusion. Isolated hepatocytes from rat metabolized phyllanthoside at a rate of 4.4 micrograms/min per 10(6) cells to form the less polar metabolite. Coculture with isolated hepatocytes decreased the cytotoxicity of phyllanthoside to A204 human rhabdomyosarcoma cell line growing in soft agarose. It is suggested that rapid metabolism of phyllanthoside in mouse as against dog might account for the lower toxicity of phyllanthoside in mouse, and might also account for the reported poor antitumor activity of IV-administered phyllanthoside in the mouse.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3698162     DOI: 10.1007/bf00293981

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

1.  Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1976-10

Review 2.  Methods for obtaining drug time course data from individual small laboratory animals: serial microblood sampling and assay.

Authors:  B H Migdalof
Journal:  Drug Metab Rev       Date:  1976       Impact factor: 4.518

Review 3.  Microsomal epoxide hydrolase. Properties, regulation and function.

Authors:  J Seidegård; J W DePierre
Journal:  Biochim Biophys Acta       Date:  1983-12-29

4.  N-demethylation of aminopyrine in vivo and in the isolated hepatocyte of the rat.

Authors:  D J Stewart; T Inaba
Journal:  Biochem Pharmacol       Date:  1979       Impact factor: 5.858

5.  High-performance liquid chromatographic assay for the antitumor glycoside phyllanthoside and its stability in plasma of several species.

Authors:  G Powis; D J Moore
Journal:  J Chromatogr       Date:  1985-07-12

6.  Activation and inactivation of cancer chemotherapeutic agents by rat hepatocytes cocultured with human tumor cell lines.

Authors:  M C Alley; G Powis; P L Appel; K L Kooistra; M M Lieber
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

7.  ENZYME-STRUCTURE RELATIONSHIPS IN THE ENDOPLASMIC RETICULUM OF RAT LIVER : A Morphological and Biochemical Study.

Authors:  L Ernster; P Siekevitz; G E Palade
Journal:  J Cell Biol       Date:  1962-12-01       Impact factor: 10.539

  7 in total
  2 in total

1.  Eukaryotic protein synthesis inhibitors identified by comparison of cytotoxicity profiles.

Authors:  Jenny Chan; Shakila N Khan; Isabelle Harvey; William Merrick; Jerry Pelletier
Journal:  RNA       Date:  2004-03       Impact factor: 4.942

2.  Isolation, identification and biological activity of a phyllanthoside metabolite produced in vitro by mouse plasma.

Authors:  D E Chapman; D J Moore; D C Melder; A Breau; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.